-
1
-
-
33750726077
-
Clinical features of metastatic bone disease and risk of skeletal morbidity
-
PID: 17062708
-
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–9s.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6243-6249
-
-
Coleman, R.E.1
-
2
-
-
75749110617
-
MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy
-
COI: 1:CAS:528:DC%2BC3cXivFWmsbo%3D, PID: 20080889
-
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.
-
(2010)
J Nucl Med
, vol.51
, pp. 311-328
-
-
Sgouros, G.1
Roeske, J.C.2
McDevitt, M.R.3
Palm, S.4
Allen, B.J.5
Fisher, D.R.6
-
3
-
-
84860677986
-
A bone marrow toxicity model for Ra-223 α-emitter radiopharmaceutical therapy
-
COI: 1:CAS:528:DC%2BC38XhtVGgs7%2FN, PID: 22546715
-
Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for Ra-223 α-emitter radiopharmaceutical therapy. Phys Med Biol. 2012;57:3207–22.
-
(2012)
Phys Med Biol
, vol.57
, pp. 3207-3222
-
-
Hobbs, R.F.1
Song, H.2
Watchman, C.J.3
Bolch, W.E.4
Aksnes, A.K.5
Ramdahl, T.6
-
4
-
-
84951906335
-
-
Cancer Therapy Evaluation Program: National Cancer Institute
-
CTEP. Common terminology criteria for adverse events (CTCAE) v4.0. Bethesda, MD: Cancer Therapy Evaluation Program, National Cancer Institute; 2015. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 1 Aug 2015.
-
(2015)
MD
-
-
-
5
-
-
20644447798
-
First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases
-
COI: 1:CAS:528:DC%2BD2MXltFeksrc%3D, PID: 15958630
-
Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–9.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4451-4459
-
-
Nilsson, S.1
Larsen, R.H.2
Fossa, S.D.3
Balteskard, L.4
Borch, K.W.5
Westlin, J.E.6
-
6
-
-
34347244905
-
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
-
COI: 1:CAS:528:DC%2BD2sXnsFKkurw%3D, PID: 17544845
-
Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94.
-
(2007)
Lancet Oncol
, vol.8
, pp. 587-594
-
-
Nilsson, S.1
Franzen, L.2
Parker, C.3
Tyrrell, C.4
Blom, R.5
Tennvall, J.6
-
7
-
-
84871926771
-
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer
-
COI: 1:CAS:528:DC%2BC38XhsVSltLvP, PID: 23000088
-
Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germá JR, O'Bryan-Tear CG, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189–97.
-
(2013)
Eur Urol
, vol.63
, pp. 189-197
-
-
Parker, C.C.1
Pascoe, S.2
Chodacki, A.3
O'Sullivan, J.M.4
Germá, J.R.5
O'Bryan-Tear, C.G.6
-
8
-
-
84897939554
-
Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-Dichloride
-
COI: 1:CAS:528:DC%2BC2cXltlaqtL8%3D, PID: 24343987
-
Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-Dichloride. J Nucl Med. 2014;55:268–74.
-
(2014)
J Nucl Med
, vol.55
, pp. 268-274
-
-
Pandit-Taskar, N.1
Larson, S.M.2
Carrasquillo, J.A.3
-
9
-
-
84858706749
-
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
-
COI: 1:CAS:528:DC%2BC38Xkt1Gmt78%3D, PID: 22341993
-
Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.
-
(2012)
Eur J Cancer
, vol.48
, pp. 678-686
-
-
Nilsson, S.1
Strang, P.2
Aksnes, A.K.3
Franzèn, L.4
Olivier, P.5
Pecking, A.6
-
10
-
-
33646894695
-
Radiotoxicity of the α-emitting bone-seeker Ra-223 injected intravenously into mice: histology, clinical chemistry and hematology
-
COI: 1:CAS:528:DC%2BD28XlvVWiu7Y%3D, PID: 16724665
-
Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottir TJ, Bruland OS, et al. Radiotoxicity of the α-emitting bone-seeker Ra-223 injected intravenously into mice: histology, clinical chemistry and hematology. In Vivo. 2006;20:325–31.
-
(2006)
In Vivo
, vol.20
, pp. 325-331
-
-
Larsen, R.H.1
Saxtorph, H.2
Skydsgaard, M.3
Borrebaek, J.4
Jonasdottir, T.J.5
Bruland, O.S.6
-
11
-
-
84888303650
-
Targeted α-particle therapy of bone metastases in prostate cancer
-
PID: 24212441
-
Jadvar H, Quinn DI. Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013;38:966–71.
-
(2013)
Clin Nucl Med
, vol.38
, pp. 966-971
-
-
Jadvar, H.1
Quinn, D.I.2
-
12
-
-
0036606104
-
Significant antitumor effect from bone-seeking, α-particle-emitting Ra-223 demonstrated in an experimental skeletal metastases model
-
COI: 1:CAS:528:DC%2BD38XksVyqsrY%3D, PID: 12036923
-
Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, α-particle-emitting Ra-223 demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–5.
-
(2002)
Cancer Res
, vol.62
, pp. 3120-3125
-
-
Henriksen, G.1
Breistol, K.2
Bruland, O.S.3
Fodstad, O.4
Larsen, R.H.5
-
13
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
COI: 1:CAS:528:DC%2BC3sXhtFKls77M, PID: 23863050
-
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
-
(2013)
N Engl J Med
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
Helle, S.I.4
O'Sullivan, J.M.5
Fosså, S.D.6
-
14
-
-
84874106208
-
Dosimetry of 223Ra-chloride: dose to normal organs and tissues
-
COI: 1:CAS:528:DC%2BC3sXkvVKmsA%3D%3D, PID: 23053328
-
Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40:207–12.
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, pp. 207-212
-
-
Lassmann, M.1
Nosske, D.2
-
15
-
-
84881630281
-
Phase I pharmacokinetic and biodistribution study with escalating doses of Ra-dichloride in men with castration-resistant metastatic prostate cancer
-
COI: 1:CAS:528:DC%2BC3sXht1Gmu7fF, PID: 23653243
-
Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1384–93.
-
(2013)
Eur J Nucl Med Mol Imaging
, vol.40
, pp. 1384-1393
-
-
Carrasquillo, J.A.1
O’Donoghue, J.A.2
Pandit-Taskar, N.3
Humm, J.L.4
Rathkopf, D.E.5
Slovin, S.F.6
-
16
-
-
84862239106
-
Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases
-
COI: 1:CAS:528:DC%2BC38XhtFKnsbvI, PID: 22513884
-
Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33:726–32.
-
(2012)
Nucl Med Commun
, vol.33
, pp. 726-732
-
-
Hindorf, C.1
Chittenden, S.2
Aksnes, A.K.3
Parker, C.4
Flux, G.D.5
-
18
-
-
16744365716
-
MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates
-
COI: 1:CAS:528:DyaK1MXivVGlsrg%3D, PID: 10025848
-
Siegel JA, Thomas SR, Stubbs JB. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37s–61s.
-
(1999)
J Nucl Med
, vol.40
, pp. 37-61
-
-
Siegel, J.A.1
Thomas, S.R.2
Stubbs, J.B.3
-
19
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
COI: 1:STN:280:DyaL3s7kvFOgsw%3D%3D, PID: 7165009
-
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
Horton, J.4
Davis, T.E.5
McFadden, E.T.6
-
20
-
-
0003954913
-
-
Lippincott Williams & Wilkins, Philadelphia, PA
-
Khan FM, The physics of radiation therapy. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
-
(2003)
The physics of radiation therapy
-
-
Khan, F.M.1
-
21
-
-
0032435802
-
Absolute organ activity estimated by five different methods of background correction
-
COI: 1:STN:280:DyaK1M%2FotlSmsA%3D%3D, PID: 9867163
-
Buijs WC, Siegel JA, Boerman OC, Corstens FH. Absolute organ activity estimated by five different methods of background correction. J Nucl Med. 1998;39:2167–72.
-
(1998)
J Nucl Med
, vol.39
, pp. 2167-2172
-
-
Buijs, W.C.1
Siegel, J.A.2
Boerman, O.C.3
Corstens, F.H.4
-
22
-
-
0024713937
-
A Monte Carlo program for the simulation of scintillation camera characteristics
-
COI: 1:STN:280:DyaK3c%2FgsValtg%3D%3D, PID: 2791527
-
Ljungberg M, Strand SE. A Monte Carlo program for the simulation of scintillation camera characteristics. Comput Methods Programs Biomed. 1989;29:257–72.
-
(1989)
Comput Methods Programs Biomed
, vol.29
, pp. 257-272
-
-
Ljungberg, M.1
Strand, S.E.2
-
23
-
-
79957662849
-
Clinical dosimetry in the treatment of bone tumours: old and new agents
-
COI: 1:STN:280:DC%2BC3M3ltFChtQ%3D%3D, PID: 21386790
-
Hindorf C, Flux GD, Ibisch C, Bodéré Kraeber F. Clinical dosimetry in the treatment of bone tumours: old and new agents. Q J Nucl Med Mol Imaging. 2011;55:198–204.
-
(2011)
Q J Nucl Med Mol Imaging
, vol.55
, pp. 198-204
-
-
Hindorf, C.1
Flux, G.D.2
Ibisch, C.3
Bodéré Kraeber, F.4
-
24
-
-
0023901242
-
Strontium-89 therapy: measurement of absorbed dose to skeletal metastases
-
COI: 1:STN:280:DyaL1c7ntFOjuw%3D%3D, PID: 3351609
-
Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med. 1988;29:549–57.
-
(1988)
J Nucl Med
, vol.29
, pp. 549-557
-
-
Blake, G.M.1
Zivanovic, M.A.2
Blaquiere, R.M.3
Fine, D.R.4
McEwan, A.J.5
Ackery, D.M.6
-
26
-
-
23044470017
-
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine
-
PID: 15937315
-
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.
-
(2005)
J Nucl Med
, vol.46
, pp. 1023-1027
-
-
Stabin, M.G.1
Sparks, R.B.2
Crowe, E.3
-
27
-
-
84897876213
-
Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP
-
COI: 1:CAS:528:DC%2BC3sXhsFKjt7fK, PID: 24077786
-
Pacilio M, Ventroni G, Basile C, Ialongo P, Becci D, Mango L. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. Eur J Nucl Med Mol Imaging. 2014;41:238–52.
-
(2014)
Eur J Nucl Med Mol Imaging
, vol.41
, pp. 238-252
-
-
Pacilio, M.1
Ventroni, G.2
Basile, C.3
Ialongo, P.4
Becci, D.5
Mango, L.6
-
28
-
-
34250354452
-
Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation
-
COI: 1:CAS:528:DC%2BD2sXmtl2jtLo%3D, PID: 17237963
-
Strigari L, Sciuto R, D’Andrea M, Pasqualoni R, Benassi M, Maini CL. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation. Eur J Nucl Med Mol Imaging. 2007;34:1031–8.
-
(2007)
Eur J Nucl Med Mol Imaging
, vol.34
, pp. 1031-1038
-
-
Strigari, L.1
Sciuto, R.2
D’Andrea, M.3
Pasqualoni, R.4
Benassi, M.5
Maini, C.L.6
-
29
-
-
34447545672
-
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases
-
COI: 1:CAS:528:DC%2BD2sXnsFOjt7k%3D, PID: 17625384
-
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28:623–30.
-
(2007)
Nucl Med Commun
, vol.28
, pp. 623-630
-
-
Liepe, K.1
Kotzerke, J.2
-
30
-
-
0026725284
-
Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma
-
COI: 1:STN:280:DyaK38zgvFSlsw%3D%3D, PID: 1613572
-
Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992;33:1316–23.
-
(1992)
J Nucl Med
, vol.33
, pp. 1316-1323
-
-
Breen, S.L.1
Powe, J.E.2
Porter, A.T.3
-
31
-
-
0032407291
-
Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP
-
PID: 9867152
-
van Rensburg AJ, Alberts AS, Louw WKA. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. J Nucl Med. 1998;39:2110–5.
-
(1998)
J Nucl Med
, vol.39
, pp. 2110-2115
-
-
van Rensburg, A.J.1
Alberts, A.S.2
Louw, W.K.A.3
-
32
-
-
0025358769
-
Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer
-
PID: 1693784
-
Maxon HR, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology. 1990;176:155–9.
-
(1990)
Radiology
, vol.176
, pp. 155-159
-
-
Maxon, H.R.1
Schroder, L.E.2
Thomas, S.R.3
Hertzberg, V.S.4
Deutsch, E.A.5
Scher, H.I.6
-
33
-
-
0025950294
-
Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo
-
PID: 1717669
-
Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991;32:1877–81.
-
(1991)
J Nucl Med
, vol.32
, pp. 1877-1881
-
-
Maxon, H.R.1
Schroder, L.E.2
Hertzberg, V.S.3
Thomas, S.R.4
Englaro, E.E.5
Samaratunga, R.6
-
34
-
-
0037824534
-
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases
-
COI: 1:CAS:528:DC%2BD3sXlt12js7w%3D, PID: 12791825
-
Liepe K, Hliscs R, Kropp J, Runge R, Knapp Jr FF, Franke WG. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med. 2003;44:953–60.
-
(2003)
J Nucl Med
, vol.44
, pp. 953-960
-
-
Liepe, K.1
Hliscs, R.2
Kropp, J.3
Runge, R.4
Knapp, F.F.5
Franke, W.G.6
-
35
-
-
0022374032
-
Strontium-89 therapy for the pain of osseous metastases
-
COI: 1:STN:280:DyaL2M7lvFymuw%3D%3D, PID: 3920361
-
Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med. 1985;26:345–8.
-
(1985)
J Nucl Med
, vol.26
, pp. 345-348
-
-
Silberstein, E.B.1
Williams, C.2
-
36
-
-
0033923590
-
Systemic radiopharmaceutical therapy of painful osteoblastic metastases
-
COI: 1:STN:280:DC%2BD3cvovVSjsw%3D%3D, PID: 11034634
-
Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol. 2000;10:240–9.
-
(2000)
Semin Radiat Oncol
, vol.10
, pp. 240-249
-
-
Silberstein, E.B.1
-
37
-
-
0034119348
-
Use of radionuclides for the palliation of bone metastases
-
COI: 1:STN:280:DC%2BD3c7psVSnsA%3D%3D, PID: 10727599
-
McEwan AJ. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000;10:103–14.
-
(2000)
Semin Radiat Oncol
, vol.10
, pp. 103-114
-
-
McEwan, A.J.1
-
38
-
-
42149153360
-
Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases
-
COI: 1:CAS:528:DC%2BD1cXks1Glu70%3D, PID: 18204850
-
Li WB, Höllriegl V, Roth P, Oeh U. Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases. Radiat Environ Biophys. 2008;47:225–39.
-
(2008)
Radiat Environ Biophys
, vol.47
, pp. 225-239
-
-
Li, W.B.1
Höllriegl, V.2
Roth, P.3
Oeh, U.4
-
39
-
-
14844361408
-
Bone-seeking radionuclides for therapy
-
COI: 1:CAS:528:DC%2BD2MXhsVeksL0%3D, PID: 15653650
-
Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46:38S–47S.
-
(2005)
J Nucl Med
, vol.46
, pp. 38-47
-
-
Lewington, V.J.1
-
40
-
-
84877358667
-
Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets
-
PID: 23615276
-
Dant JT, Richardson RB, Nie LH. Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets. Phys Med Biol. 2013;58:3301–19.
-
(2013)
Phys Med Biol
, vol.58
, pp. 3301-3319
-
-
Dant, J.T.1
Richardson, R.B.2
Nie, L.H.3
-
41
-
-
33746707858
-
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
-
COI: 1:CAS:528:DC%2BD28XhtFWhsbfK, PID: 17062709
-
Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–7s.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6250-6257
-
-
Bruland, Ø.S.1
Nilsson, S.2
Fisher, D.R.3
Larsen, R.H.4
-
42
-
-
79959437613
-
Alpha-particle microdosimetry
-
COI: 1:CAS:528:DC%2BC3MXhsVCqsLbL, PID: 22201713
-
Chouin N, Bardies M. Alpha-particle microdosimetry. Curr Radiopharm. 2011;4:266–80.
-
(2011)
Curr Radiopharm
, vol.4
, pp. 266-280
-
-
Chouin, N.1
Bardies, M.2
|